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Abstract
Background: The C-terminal region of Plasmodium falciparum merozoite surface protein-1 (PfMSP-119) is a leading
malaria vaccine candidate antigen. However, the existence of different variants of this antigen can limit efficacy of
the vaccine development based on this protein. Therefore, in this study, the main objective was to define the
frequency of PfMSP-119 haplotypes in malaria hypoendemic region of Iran and also to analyse cross-reactive and/or
variant-specific antibody responses to four PfMSP-119 variant forms.
Methods: The PfMSP-119 was genotyped in 50 infected subjects with P. falciparum collected during 2006-2008.
Four GST-PfMSP-119 variants (E/TSR/L, E/TSG/L, E/KNG/F and Q/KNG/L) were produced in Escherichia coli and
naturally occurring IgG antibody to these proteins was evaluated in malaria patients’ sera (n = 50) using ELISA. To
determine the cross-reactivity of antibodies against each PfMSP-119 variant in P. falciparum-infected human sera, an
antibody depletion assay was performed in eleven corresponding patients’ sera.
Results: Sequence data of the PfMSP-119 revealed five variant forms in which the haplotypes Q/KNG/L and Q/KNG/
F were predominant types and the second most frequent haplotype was E/KNG/F. In addition, the prevalence of
IgG antibodies to all four PfMSP-119 variant forms was equal and high (84%) among the studied patients’ sera.
Immunodepletion results showed that in Iranian malaria patients, Q/KNG/L variant could induce not only cross-
reactive antibody responses to other PfMSP-119 variants, but also could induce some specific antibodies that are
not able to recognize the E/TSG/L or E/TSR/L variant forms.
Conclusion: The present findings demonstrated the presence of non-variant specific antibodies to PfMSP-119 in
Iranian falciparum malaria patients. This data suggests that polymorphism in PfMSP-119 is less important and one
variant of this antigen, particularly Q/KNG/L, may be sufficient to be included in PfMSP-119-based vaccine.
Background
Plasmodium falciparum is a major global health pro-
blem and is responsible for most cases of severe malaria
and over one million deaths annually [1]. Increasing the
drug-resistant P. falciparum strains [2,3] and also insec-
ticide resistant Anopheles mosquito in different malaria-
endemic regions of the world emphasizes the need for
new controlling tools and strategies such as vaccine to
combat P. falciparum.
Development of an effective vaccine against P. falci-
parum malaria has been a long-standing goal for malaria
research and despite many decades of study, no effective
vaccine against malaria parasite exists [4]. Genetic diver-
sity in protective antigens is responsible for challenging
in development of an effective malaria vaccine. This
phenomenon will increase the parasite ability to evade
immune responses, as a result, produce “vaccine-resis-
tant parasite” and, therefore, threaten vaccine efficacy.
To overcome the extensive genetic diversity in P. falci-
parum and develop protective vaccines, first, it is needed
to understand the distribution of polymorphisms and
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cine antigen in various endemic populations before con-
duction of vaccine trials.
Merozoite surface protein 1 (MSP-1) is the major pro-
tein on the surface of the blood stage of the parasite.
Before erythrocyte invasion, the entire MSP-1 complex
is shed, except for the C-terminal 19-kDa (MSP-119),
which remains on the surface as the merozoite enters
the erythrocyte [5]. This fragment has been the focus of
malaria vaccine development and consists of two epider-
mal growth factors (EGF)-like domains, each containing
six cysteine residues [6], which are thought to have an
important function in erythrocyte invasion [7,8]. In vitro
and in vivo studies have shown that antibodies against
PfMSP-119 can prevent invasion of merozoites into red
blood cells. These antibodies could block the cell cycle
of parasites [9-14]. In addition, field studies also showed
that naturally acquired antib o d i e st ot h i sa n t i g e nc a n
inhibit erythrocyte invasion and, therefore, protect from
clinical malaria [15-19].
Single nucleotide polymorphisms (SNPs) in PfMSP-119
are caused limited sequence variations [20-22]. These
mutations are at position 1644 (E/Q) in the first EGF
domain and at positions 1691 (T/K), 1700 (S/N), 1701
(R/G) and 1716 (L/F) of the second EGF domain which
lead to create different PfMSP-119 variants (Q/KNG/L,
E/KNG/L, E/KNG/F, Q/KNG/F, E/TSR/L, Q/TSR/L, Q/
TSR/F, E/TSR/F, E/TSG/L etc.) that have been reported
from global malaria endemic regions. Different studies
have demonstrated cross-reactive antibody responses
between PfMSP-119 variant forms [16,23] with some
specific recognition [16,23-25]. These specific antibody
responses could be associated to polymorphic amino
acids within the second EGF-like domain [16,23].
A study by Singh et al. [26] showed that immunized
Aotus monkeys with PfMSP-119-Q/KNG and/or PfMSP-
119- E/TSR variant(s) of PfMSP-119 could develop anti-
bodies to protect against challenge with P. falciparum
Q/KNG parasite. Interestingly, limited studies have
investigated the natural acquired immunity against dif-
ferent PfMSP-119 variants in Kenya [23], India [27] and
Peru [28] and have shown cross-reactivity in naturally
acquired immunity arisen to PfMSP-119 variants in spite
of the presence of specific antibody responses.
Since diversity is encountered with development of
effective malaria vaccine, having information on PfMSP-
119 genotype from clinical P. falciparum isolates and
study on specific immunity to these variant forms in
malaria endemic areas with different levels of transmis-
sion are important for selection which alleles to be
included in multivalent vaccines. The earlier study con-
ducted in malaria hypoendemic areas of Iran during
2001-2005, detected five PfMSP-119 variants (E/TSR/L,
E/TSG/L, E/KNG/F, Q/KNG/F and Q/KNG/L) with
E/TSG/L as predominant form [22]. The main objective
of this study was to define the frequency of PfMSP-119
haplotypes over 2006 to 2008 in malaria hypoendemic
regions of Iran and then to investigate cross-reactive
and/or variant specific antibody responses to the circu-
lating PfMSP-119 forms. This study will help us to
understand the natural antibody responses (variant spe-
cific or cross-reactive antibody responses) to different
PfMSP-119 variants of P. falciparum parasites that need
to take into account in developing a polyvalent MSP-
119-based vaccine.
Methods
Subjects and blood sample collection
This study was performed in Sistan and Baluchistan
province, Iran, where 10% of malaria patients suffered
from falciparum malaria. The burden of malaria
declined gradually over the last few years from 15,712
total cases in 2007 to 6,122 in 2009. In this region, most
of the patients are adults and may experience several
infections by P. falciparum and/or Plasmodium vivax
with clinical symptoms. There is no record of severe
malaria or death due to malaria. In this investigation,
blood samples were collected from 50 P. falciparum
infected individuals with symptomatic uncomplicated
malaria attending at the Malaria Health Center in
Chabahar Public Health Department in Sistan and Balu-
chistan province, south-eastern Iran during 2006 to
2008, as determined by Giemsa-stained thick smears.
Age of the patients ranged between 5 to 75 years (mean
26.96) and 42 and 8 were male and female, respectively.
Two ml venous blood was collected in tubes containing
EDTA, and after centrifugation at 4,000 rpm for 10 min,
plasma was collected and stored at -20°C until use. The
study was explained in detail to all participants, and
either they or their parents or legal guardians gave their
signed informed consent. This study was approved by
the Ethical Review Committee of Research in Institut
Pasteur Iran.
PCR amplification and sequencing of PfMSP-119
Parasite genomic DNA was prepared by using the com-
mercially available DNA purification kit (Promega,
Madison, WI, USA) and kept at -20°C until use. Detec-
tion of Plasmodium species in samples was performed
by both microscopy and nested-PCR amplification as
described previously [29]. To define the sequence poly-
morphism in Pfmsp-119 gene (corresponding to 4894 to
5242 bp) the following primers were used:
PfF: TCCAAggATCCTTAAACATTTCACAACAC
PfR: TCCTACTCgAgTTAAATgAAACTgTATAAT
Amplified fragments (n = 50) were gel-purified using
the QIAGEN DNA purification kit (Qiagen, Germany)
following the manufacturer’s instructions. Direct
Zakeri et al. Malaria Journal 2010, 9:257
http://www.malariajournal.com/content/9/1/257
Page 2 of 8sequencing of the DNA fragments was performed in
both directions for each PCR product using the dideoxy
chain termination procedure (Chemistry V3.1, Applied
Biosystems) and also the 3730XL DNA analyser
(Applied Biosystems) by MilleGen sequencing service
(Labege, France). Nucleotide and amino acid sequences
were aligned and compared by using ClustalX (with
manual editing), with the published sequences, K1
(X03371) and MAD20 (X05624). The representing
nucleotide sequences data of different Pfmsp-119 variants
reported in this article, were submitted to EMBL, Gen-
Bank and DDJB databases under the accession numbers
HM569746-HM569750.
Recombinant PfMSP-119
The PfMSP-119 variants (E/TSR/L, E/TSG/L, E/KNG/F
and Q/KNG/L) with GenBank accession nos.
HM569746, HM569747, HM569748 and HM569750,
respectively) were cloned and expressed in Escherichia
coli as recombinant proteins fused to the C-terminus of
glutathione S-transferase (GST) of Schistosoma japoni-
cum using the pGEX-KG vector.
Briefly, overnight culture from a single colony of PfMSP-
119 specific E. coli was expanded in TB (pH 7.2) containing
ampicillin (100 μg/ml) at 30°C with shaking (150 rpm)
until optical density (OD) 0.6-0.7 at 600 nm was reached.
The expression of GST-PfMSP-119 was induced with 0.5
mM IPTG (Sigma, USA). The culture was further grown
for 4 h, and the cell pellet was lysed on ice by sonication
(Ultraschallprozessor, Germany) with 10 sonication cycles,
each consisting of 20 s pulses at 20 s intervals. The bacter-
ial lysate was centrifuged at 12,000 rpm at 4°C for 30 min
and the supernatant was incubated with glutathione
sepharose 4B resin (Amersham Biosciences, USA) at 4°C
for one hour and the resin was packed into a column. The
column was washed with a 10-column volume of PBS1X,
pH 7.4. The bound protein was eluted with a buffer con-
taining 50 mM Tris-HCl, 10 mM reduced glutathione, pH
8. The fractions containing PfMSP-119 were desalted with
Econo-Pac 10 DG columns (BioRad, USA) according to
the manufacture’s manual and then concentrated with a
concentrator (Eppendorf, Germany). The elutes were ana-
lysed by SDS-PAGE on 12% gels under reducing condi-
tions and the concentration of the protein was determined
using Bradford assay by a spectrophotometer (Eppendorf,
Germany). To confirm the recombinant protein, Western
blotting was carried out by standard protocols, with
P. falciparum infected human sera. Control GST protein
was prepared from E. coli with only GST gene constructs.
ELISA
Anti-PfMSP-119 in patients’ sera was evaluated by
ELISA. In brief, Maxisorp flat-bottomed 96-well micro-
plates (Grainer, Labortechnic, Germany) were coated
with 100 ng/well of any of the four recombinant affi-
nity-purified GST-PfMSP-119 (E/TSR/L, E/TSG/L,
E/KNG/F, and Q/KNG/L) or with GST alone in 0.06 M
carbonate-bicarbonate buffer (pH 9.6) and incubated at
4°C overnight. The plates were washed with PBS-Tween
and blocked with 2% bovine serum albumin (BSA) for
one hour at room temperature (RT). A volume of
100 μl of diluted plasma of individual patient plasma
(1:200) was added in duplicate to coated plates and
incubated for 2 h at RT. After washing, the plates were
incubated with 100 μl of horseradish peroxidase-conju-
gated goat anti-human IgG Abs (1:25,000, Sigma, USA).
The enzyme reaction was developed with o-phenyledia-
mine dihydrochloride-H2O2 (Sigma, USA) and stopped
with 2N H2SO4. The OD was measured using a micro-
plate reader (Biotech, USA) at 492 nm, and the mean
value of each pair of wells (after substraction of OD of
GST) was calculated. A pool of adult Iranian immune
sera from malaria endemic region with patent P. falci-
parum infection and 35 serum samples from healthy
non-exposed Iranian from outside malaria endemic
regions were used as positive and negative controls,
respectively, in each plate. The cut-off value for positive
plasma was considered as the mean plus 3 standard
deviation (SD) of OD readings of negative samples
(n = 35).
Immunodepletion ELISA
To determine the cross-reactivity of antibodies against
each PfMSP-119 variants in P. falciparum infected
human sera, an antibody depletion assay was performed
in eleven corresponding patients’ sera as described ear-
lier [27]. Briefly, the 96-well primary plates were coated
with 100 ng/well of each of PfMSP-119 recombinant
antigen, namely E/TSR/L, E/TSG/L, E/KNG/F and Q/
KNG/L antigens and blocked with 3% BSA in PBS1X
for one hour at RT. After blocking, all the plates were
washed with 0.05% Tween 20 in PBS and then with PBS
(pH 7.4). The first two wells in the first column were
incubated for 30 min with sera of the respective
sequence variants at a dilution of 1:1000 in PBS-T con-
taining 1% BSA, while the remaining wells contained
only wash buffer. After 30 min, the sera from the first
two wells were transferred into the next wells in the
second column and incubated for another 30 min.
These serial incubations were carried out until all of the
antibodies with a particular variant antigen were
depleted, as determined by a standard ELISA. In this
study, it was observed that antigen specific antibodies
were completely removed from the respective sera after
ten serial transfers. After the last transfer, the antibody-
depleted sera were transferred into the secondary ELISA
plates coated with the four PfMSP119 variants (100 ng
of each variant/well) and incubated for 30 min. Finally,
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washed three times with PBS-T and incubated with
horseradish peroxidase-labeled anti-IgG immunoglobulin
(Sigma, USA) for one hour and the ELISA was com-
pleted as described above. The reactivity of each
depleted sera with the other three haplotypes was
compared with that of the undepleted sera.
Statistical analysis
A database was created with SPSS 16.0 for windows
(SPSS Inc., USA). The Spearman’s correlation test was
used to correlate antibody levels in all four PfMSP-119
variant types. Kraskall-Wallis test was also performed to
compare the antibody levels with corresponding
infected-variant forms. The non-parametric Friedman
test was applied to compare the variances between the
levels of IgG responses to all four variants. In addition,
Wilcoxan test was used to compare the IgG levels
between two variant types for paired data. In all tests, P
value < 0.05 was considered significant.
Results
Genotyping of Pfmsp-119 gene
In this study, sequence comparison of the 19-kDa frag-
ment of MSP-1 in a natural population of P. falciparum
(n = 50) in Iran with the corresponding sequences of
the PfMAD20 (X05624) and PfK1 (X03371) showed five
distinct haplotypes, namely E/TSR/L (n = 10), E/TSG/L
(n = 3), E/KNG/F (n = 11), Q/KNG/F (n = 13) and Q/
KNG/L (n = 13). The Pfmsp-119-Q/KNG/F and Pfmsp-
119-Q/KNG/L variant alleles were predominant
haplotypes.
Antibody responses to PfMSP-119 variants
All the four GST-PfMSP-119 variants were expressed in
E. coli in a soluble form and the purified proteins were
analysed by SDS-PAGE and showed a molecular mass of
~37 kDa. Total IgG antibody responses to all four var-
iants of PfMSP-119 were analysed on 50 sera samples,
indicating high, medium and low positives as well as
negative values for each variant in a pair-wise manner
(Figure 1). Of the 50 individuals, 42 (84%) and 8 (16%)
were positive and negative for all allele variants, respec-
tively. These eight negative responders harboured para-
sites with E/TSR/L (n = 2), Q/KNG/F (n = 2), E/KNG/F
(n = 1) and Q/KNG/L (n = 3) haplotypes (Figure 1).
Overall, no clear association was found between the five
PfMSP-119 variants of infecting P. falciparum parasite
and antibody response among studied patients (P > 0.05,
Kruskall-wallis; Figure 1).
The highest OD mean (± SD) value was for Q/KNG/L
(1.54 ± 0.694, cut-off 0.26), followed by E/TSG/L (1.25
± 0.663, cut-off 0.2) and E/KNG/F (1.22 ± 0.631, cut-off
0.37) and E/TSR/L (1.09 ± 0.566, cut-off 0.3).
Comparing values of the IgG for all four PfMSP-119 var-
iants indicated a significant difference (P = 0.003, Fried-
man statistic = 14.13). However, the comparison
between two variant forms showed a significant differ-
ence between E/TSR/L and Q/KNG/L (P < 0.0001),
E/TSG/L and Q/KNG/L (P < 0.0001), E/KNG/F and
Q/KNG/L (P = 0.044), using Wilcoxan test (Table 1).
The highest responses matched for E/TSR/L and
E/TSG/L (78%) and E/TSR/L and E/KNG/F (70%)
( T a b l e1 ) ;h o w e v e r ,t h eE / K N G / Fm a t c h e dQ / K N G / L
62% of the time. In addition, in a paired correlation ana-
lysis comparing the continuous measurements to the
four allele variants, E/TSR/L and E/TSG/L were found
at the highest rate (r = 0.866) and the lowest correlation
coefficient was found to be between E/TSG/L and
E/KNG/F (r = 0.670). Correlations between all pairs
were significant (P < 0.0001, Table 2).
Cross-reactive and variant-specific responses
In this investigation, to determine the cross-reactive and
variant-specific responses to the four PfMSP-119 variants
during natural infection, an ELISA depletion assay was
used. In this assay, the cross-reactive antibodies between
antigens were depleted with all the variants (74% to 85%
reduction in reactivity) and therefore, only antibodies to
different sites of antigen remain to bind in secondary
plate. Sequencing analysis showed that the eleven exam-
ined patients harboured different PfMSP-119 variants
and also they had a high level of total IgG against four
PfMSP-119 variants (Figure 2). To indicate type-specific
antibody responses to Q-/E-, -TSR/-TSG/-KNG, all the
eleven examined patients’ sera were depleted by four
examined variants and the result showed that sera
depleted with Q/KNG/L allele type did not have a posi-
tive antibody response to any of four allele types
(Figure 2). However, sera depleted with either E/TSR/L
or E/TSG/L allele types recognized Q/KNG/L and
E/KNG/F, indicating specific antibody responses to Q-
and/or -KNG (Figure 2). With respect to the Q- specific
antibody responses, depleted sera with E/KNG/F recog-
nized Q/KNG/L allele type. Overall, it was observed that
after antibody depletion with all four variant forms,
eight patients had low-level specific antibody to Q- and
-KNG. Of these eight sera samples, 7 and 8 had specific
antibody responses to -KNG and Q-, respectively.
Discussion
The development of MSP-1 vaccine has focused on the
C-terminal 19-kDa fragment (PfMSP-119) and antibodies
against this antigen may block parasite invasion into
erythrocytes, leading to reduction in parasitaemia and
thus protection against the disease [9,30]. This antigen
is also recognized by human antibodies [31] that could
reduce the risk of clinical malaria [15,16,19,32,33]. The
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Page 4 of 8Figure 1 Patterns of total IgG responses to four PfMSP-119 variants in Iranian individuals infected with P. falciparum isolate. Infected
PfMSP-119 variant forms in each patient were detected by sequencing analysis. Ages are given in years. Antibody reactivity of each sample is
measured by ELISA. Cut-off values are 0.2, 0.3, 0.37 and 0.26 for IgG responses to E/TSG/L, E/TSR/L, E/KNG/F, and Q/KNG/L variants, respectively.
The OD means values for IgG responses have been divided into the following groups: OD > 2: High-positive antibody responses. 1 > OD > 2:
Medium-positive responses. OD < 1: Low-positive responses. OD < Cut-off: Negative.
Table 1 Frequency of positive antibody responses to four
PfMSP-119 variant forms in a pair-wise manner
PfMSP-119 variants Pair-wise manner (%) P value (Wilcoxan test)
E/TSR/L-E/TSG/L 39/50 (78) = 0.273
E/TSR/L-E/KNG/F 35/50 (70) = 0.251
E/TSR/L-Q/KNG/L 30/50 (60) < 0.0001
E/TSG/L-E/KNG/F 31/50 (62) = 0.735
E/TSG/L-Q/KNG/L 31/50 (62) < 0.0001
E/KNG/F-Q/KNG/L 31/50 (62) = 0.044
P value < 0.05 was considered significant.
Table 2 Correlation analysis of IgG antibody responses in
four PfMSP-119 variant forms
PfMSP-119 variants Correlation coefficient P value
E/TSR/L-E/TSG/L r = 0.866 < 0.0001
E/TSR/L-E/KNG/F r = 0.738 < 0.0001
E/TSRL-Q/KNG/L r = 0.844 < 0.0001
E/TSG/L-E/KNG/F r = 0.670 < 0.0001
E/TSG/L-Q/KNG/L r = 0.839 < 0.0001
E/KNG/F-Q/KNG/L r = 0.709 < 0.0001
The P value denotes the Spearman correlation coefficient. P value < 0.05 was
considered significant.
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sence of limited polymorphisms in EGF-like domains of
this fragment might compromise its use as a vaccine
candidate. Therefore, the purpose of this study was
whether sequence polymorphisms in Pfmsp-119 in
P. falciparum isolates from malaria hypoendemic
regions in Iran influence the recognition and specificity
of naturally occurring antibody to the four sequence
types of PfMSP-119 antigens (E/TSR/L, E/TSG/L,
E/KNG/F and Q/KNG/L), since protective immunity is
thought to target this molecule.
Sequence data of the PfMSP-119 revealed that the hap-
lotypes Q/KNG/L and Q/KNG/F were predominant var-
iant forms and the second most frequent haplotype was
E / K N G / Fd u r i n g2 0 0 6 -2 0 0 8 .H o w e v e r ,a ne a r l i e rm o l e -
cular study, in the same region revealed five sequence
patterns, in which E/TSG/L variant form was the predo-
minant haplotype among Iranian isolates during 2001-
2005 [22]. Although, in this study, the Q/KNG/L-bearing
parasites are predominant over E/TSR/L or E/TSG/L
parasites, the prevalence of antibodies to all four PfMSP-
119 variant forms was equal and high (84%). The reason
could be that Iranian malaria patients were often exposed
to mixed parasite variant sequences of PfMSP-119 over
time and developed specific polyclonal antibodies against
multiple variants in a mixed infection. Regarding to sero-
negative individuals, three oft h e mh a df i r s te x p o s u r et o
the Plasmodium infection and the rest (n = 5) have not
been infected with this parasite (based on questionnaire)
recently and, in fact, in the absence of boosting, antibody
responses reduce to a detectable level.
In malaria endemic regions, it is difficult to distinguish
specific antibodies responses from antibodies to conserved
determinants of antigen in naturally infected individuals
who were exposed to mixed parasite variant sequence over
time. This may be further complicated if the past histories
of infection remain unclear. To evaluate the variant speci-
fic responses to PfMSP-119,t h eI g Ga n t i b o d yt oe a c ho f
the examined variants was analysed using immunodeple-
tion assay. The results showed that Q/KNG/L-infected
sera depleted with the same variant were unable to diag-
nose other PfMSP-119 variant forms. However, if it
depleted with E/TSR/L, E/TSG/L or E/KNG/F variants,
IgG antibody response was observed against Q/KNG/L
that could be explained by specific IgG response to epitope
containing Q- (at 1644) residue. It is also important to
note that E/KNG/F-infected sera depleted with E/TSR/L
variant were able to diagnose Q/KNG/L but not E/KNG/F
Figure 2 Immunodepletion results showing cross-reactive and specific antibodies in the sera of infected patients with P. falciparum
isolates. a) Sera from patients infected with E/TSR/L sequence type (n = 3), b) E/TSG/L sequence type (n = 2), c) E/KNG/F sequence type (n = 3)
and d) Q/KNG/L sequence type (n = 3). The cross-reactive antibodies between antigens were depleted with all four variant forms. The mean
antibody OD values are shown and error bars indicate the SD. The horizontal line shows the cut-off values.
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response to epitope containing Q- (at 1644) residue. This
might be explained by past infection of these individuals
with Q/KNG/L variant form. In addition, Q/KNG/L-
infected sera depleted with E/TSG/L and E/TSR/L had
low-positive IgG response to E/KNG/F due to the specific
response to epitope containing -KNG (at 1691, 1700 and
1701) residues, which is highly exposed to immune system
[34,35]. However, based on the previous studies, the -F/-L
(at 1761) residue is located in the inter-domain region of
the two EGF domains, with limited surface exposure
[34,35] and therefore, dose not seem to contribute as a
major B-cell epitope. In total, the results showed that in
Iranian individuals who were infected with different
PfMSP-119 variants could induce not only cross-reactive
antibody responses to heterologous variants but also could
induce some specific antibodies to homologous variant.
Moreover, E/TSG/L and E/TSR/L did not induce specific
antibody responses to epitopes containing E- (at 1644),
-TSG (at 1691, 1700 and 1701) or -TSR (at 1691, 1700
and 1701) residues. Therefore, it is suggested that the
majority of antibody responses have sharing B-cell
epitopes and the variant- specific immune response is to
epitopes containing Q- (at 1644) and in somewhat to
-KNG (at 1691, 1700 and 1701) residues. Although the
earlier studies suggested that antibodies to PfMSP-119 are
associated with protection [16,17,26,36], further study is
required to analyse whether these non-variant antibody
responses to PfMSP-119 are associated with clinical
protection and parasitaemia.
Conclusion
In summary, due to the presence of antigenic diversity in
vaccine antigen, it may be necessary to develop a polyva-
lent vaccine that would increase the cost of developing
and manufacturing vaccines. Therefore, it may be possi-
ble to select an antigen with limited polymorphisms that
its variant forms are recognized by cross-protective anti-
bodies. In this investigation, Iranian individuals who were
exposed to falciparum malaria develop IgG antibodies to
conserved B-cell epitopes of different PfMSP-119 variant
forms that this is in line with the previous studies in
Kenya [17,23], India [27] and Peru [28]. The present find-
ings also suggest that possibly, polymorphisms in PfMSP-
119 antigen could be less important and one variant of
this antigen, especially widely distributed Q/KNG/L, may
be sufficient to be included in PfMSP-119-based vaccine.
The impact of these cross-reactive antibodies to block
parasites invasion into the erythrocyte needs further
investigation to be elucidated.
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